mirabegron CAS NO.223673-61-8

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Haikang is looking forward to heading for win-win cooperation and a brilliant future with you!

Mirabegron mainly relaxes the bladder detrusor and increases its stability by acting on the β3 receptor. In human detrusor cells and urethral epithelial cells, a total of 3 β receptor subtypes (β1, B2 and β3) were found. The mRNA Chemicalbook of β3 receptor is mainly expressed on human detrusor smooth muscle cells, accounting for β receptors in bladder tissue 97% of mRNA. The expression of β receptor mRNA and the function of its signaling pathway suggest that β3 receptor plays a mainstay role in normal and diseased bladder.

Mirabegron easily interacts with clinically relevant drugs such as cytochrome CYP2D6 substrates and CYP3A4 inhibitors. Studies have shown that Mirabegron can increase the plasma exposure of desimipramine and metoprolol (CYP2D6 substrate drugs), reversibly prolonging Chemicalbook's long drug half-life. Other studies have shown that different doses of ketoconazole (a strong CYP3A4 inhibitor) can inhibit the clearance of Mirabegron in healthy adults, while repeated doses of rifampicin (induces CYP3A4 metabolism) can cause moderate Mirabex Decreased plasma concentration of trironuron.

Mirabegron easily interacts with clinically relevant drugs such as cytochrome CYP2D6 substrates and CYP3A4 inhibitors. Studies have shown that Mirabegron can increase the plasma exposure of desimipramine and metoprolol (CYP2D6 substrate drugs), reversibly prolonging Chemicalbook's long drug half-life. Other studies have shown that different doses of ketoconazole (a strong CYP3A4 inhibitor) can inhibit the clearance of Mirabegron in healthy adults, while repeated doses of rifampicin (induces CYP3A4 metabolism) can cause moderate Mirabex Decreased plasma concentration of trironuron.